Yakananga Kutengeswa kubva kuChina Factory CAS 1006376-62-0(1R,2R)-2-(3,4-difluorophenyl)cyclopropane carboxaMide Hot Sale Stock

Ticagrelor is an oral antiplatelet drug, zita rayo reAmerican brand inonzi Brilinta, uye zita rayo reEuropean brand ndiBrilique. Ticagrelor is reversible platelet adenosine diphosphate (ADP) receptor antagonist yakagadzirirwa kudzivirira maplatelet kubva pakunamatira pamwe chete uye kuumba ropa rekuvhara ropa rinogona kutungamirira kukurwadziwa kwemoyo uye kurohwa. MuUnited States, ticagrelor yakatanga kubvumirwa neFDA muna July 2011 kuitira kurapwa kwevarwere vakuru vane acute coronary syndrome (ACS). Clinical data inoratidza kuti ticagrelor inonyanya kushanda kupfuura clopidogrel mukuderedza kufa kwemoyo kweinenge mwedzi 12 mushure mechiitiko cheAACS. Mukuwedzera, ticagrelorChemicalbook yakaderedzawo chiitiko che stent thrombosis (ST) kune varwere vakanga vagamuchira stents kurapa ACS. Muna Chikumi 2020, AstraZeneca yakazivisa kuti iyo US Food and Drug Administration (FDA) yakabvumidza iyo anticoagulant Brilinta (ticagrelor) kuti ishandiswe kune varwere vane njodzi yakanyanya coronary artery disease (CAD) kudzikisa njodzi yekutanga kurova kwemoyo. kana njodzi yesitiroko. Muna Mbudzi 2020, AstraZeneca yakazivisa kuti iyo US Food and Drug Administration (FDA) yakanga yabvumidza chiratidzo chitsva cheiyo anticoagulant Brilinta (ticagrelor), pamwe chete neaspirin, yekurapa acute ischemia. Mune varwere vane hemorrhagic sitiroko kana yakanyanya-njodzi yenguva pfupi ischemic kurwisa (TIA), inoderedza njodzi yekutevera sitiroko.